The abstract is read at the publisher; the summary is JClub's.
Zoledronic acid blocks secretory autophagy in osteoclasts by inhibiting autophagic flux and delaying autophagy-related protein degradation, preventing secretion of CTSK, ACP5/TRAP, and MMP9.
- Why it matters: Bisphosphonates inhibit osteoclast bone-resorptive activity, but how autophagy contributes to this drug effect is unclear, limiting mechanistic understanding for bone disease therapy.
- What they did: Osteoclasts were treated with non-apoptotic doses of zoledronic acid, which inhibited autophagic flux and autolysosome formation by suppressing RAB7 prenylation; osteoclast-specific rab7 conditional knockout mice were also tested.
- The result: Zoledronic acid prevented cleavage and secretion of secretory proteins essential for bone resorption, and rab7 conditional knockout mice developed osteopetrotic phenotypes, supporting autophagy targeting in osteoclasts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.